PRDM1 is a tumor suppressor gene in natural killer cell malignancies

Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20119-24. doi: 10.1073/pnas.1115128108. Epub 2011 Dec 5.

Abstract

Natural killer cell lymphoma (NKCL) constitutes a rare and aggressive form of non-Hodgkin lymphoma, and there is little insight into its pathogenesis. Here we show that PRDM1 is a tumor suppressor gene in NKCLs that is inactivated by a combination of monoallelic deletion and promoter CpG island hypermethylation. We observed monoallelic deletion of PRDM1 loci in 8 of 18 (44%) NKCL cases. The other allele showed significant promoter methylation in 12 of 17 (71%) cases. In support of its role as a tumor suppressor gene, the reconstitution of PRDM1 in PRDM1-null NK cell lines led to G2/M cell cycle arrest, increased apoptosis, and a strong negative selection pressure with progressive elimination of PRDM1-expressing cells, which was enhanced when IL-2 concentration is limiting. We observed a progressive increase in PRDM1 expression--in particular, PRDM1α--in normal NK cells in response to IL-2 and in normal NK cells activated with an engineered NK cell target, K562-Cl9-mb21, suggesting its role in NK cell homeostasis. In support of this role, knockdown of PRDM1 by shRNA in normal NK cells resulted in the positive selection of these cells. We identified MYC and 4-1BBL as targets of PRDM1 in NK cells. Disruption of homeostatic control by PRDM1 may be an important pathogenetic mechanism for NKCL.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects
  • Biopsy
  • Cell Division / drug effects
  • Cell Division / genetics
  • Culture Media / pharmacology
  • DNA Copy Number Variations / drug effects
  • DNA Copy Number Variations / genetics
  • DNA Methylation / drug effects
  • DNA Methylation / genetics
  • DNA Mutational Analysis
  • G2 Phase / drug effects
  • G2 Phase / genetics
  • Gene Expression Regulation, Neoplastic / drug effects
  • Gene Knockdown Techniques
  • Gene Silencing / drug effects
  • Humans
  • Interleukin-2 / metabolism
  • Interleukin-2 / pharmacology
  • Killer Cells, Natural / drug effects
  • Killer Cells, Natural / metabolism
  • Killer Cells, Natural / pathology*
  • Lymphoma, Non-Hodgkin / genetics*
  • Lymphoma, Non-Hodgkin / pathology*
  • Positive Regulatory Domain I-Binding Factor 1
  • Promoter Regions, Genetic / genetics
  • RNA, Small Interfering / metabolism
  • Repressor Proteins / genetics*
  • Repressor Proteins / metabolism
  • Time Factors
  • Transduction, Genetic
  • Tumor Suppressor Proteins / genetics*
  • Tumor Suppressor Proteins / metabolism

Substances

  • Culture Media
  • Interleukin-2
  • RNA, Small Interfering
  • Repressor Proteins
  • Tumor Suppressor Proteins
  • PRDM1 protein, human
  • Positive Regulatory Domain I-Binding Factor 1